Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors

1 Jul 2025

Abstract excerpt

Effective clinical management of patients with cancer requires highly accurate diagnosis, precise therapy selection, and highly sensitive monitoring of disease burden. Caris Assure is a multifunctional blood-based assay that couples whole exome and whole transcriptome sequencing on plasma and leukocytes with advanced machine learning techniques to satisfy all three clinical testing needs on one platform. Caris...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Radiomics and Machine Learning in Medical Imaging
Share to Single-cell and spatial transcriptomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40596693
DOI: 10.1038/s41598-025-08986-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumorsPMID 40596693Read ↗

AI enabled exome and transcriptome liquid biopsy platform spanning the continuum of care in oncologySemantic proximity Read ↗

Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assaySemantic proximity Read ↗

Clinical Development of Molecular Residual Disease (MRD) and Multi-Cancer Early Detection (MCED) using Liquid Biopsy Multiomics with Artificial Intelligence (AI)Semantic proximity Read ↗

Liquid biopsies across the cancer care continuum.Semantic proximity Read ↗

Bridging Discovery and Treatment: Cancer BiomarkerSemantic proximity Read ↗

A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)Semantic proximity Read ↗

Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer PatientsSemantic proximity Read ↗

Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers.Semantic proximity Read ↗

Analytical validation and clinical utilization of K-4CARE<sup>TM</sup>: a comprehensive genomic profiling assay with personalized MRD detectionSemantic proximity Read ↗

Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.Semantic proximity Read ↗

A prospective national precision medicine trial comparing blood and tissue profiling in patients with Cancer of Unknown Primary (CUPCOMP)Semantic proximity Read ↗

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.